BACKGROUND AND PURPOSE: Obestatin is a recently discovered gastrointestinal peptide with established metabolic actions, which is linked to diabetes and may exert cardiovascular benefits. Here we aimed to investigate the specific effects of obestatin on vascular relaxation. EXPERIMENTAL APPROACH: Cumulative relaxation responses to obestatin peptides were assessed in rat isolated aorta and mesenteric artery (n≥ 8) in the presence and absence of selective inhibitors. Complementary studies were performed in cultured bovine aortic endothelial cells (BAEC). KEY RESULTS: Obestatin peptides elicited concentration-dependent relaxation in both aorta and mesenteric artery. Responses to full-length obestatin(1-23) were greater than those to obestatin(1-10) and obestatin(11-23). Obestatin(1-23)-induced relaxation was attenuated by endothelial denudation, l-NAME (NOS inhibitor), high extracellular K(+) , GDP-β-S (G-protein inhibitor), MDL-12,330A (adenylate cyclase inhibitor), wortmannin (PI3K inhibitor), KN-93 (CaMKII inhibitor), ODQ (guanylate cyclase inhibitor) and iberiotoxin (BK(Ca) blocker), suggesting that it is mediated by an endothelium-dependent NO signalling cascade involving an adenylate cyclase-linked GPCR, PI3K/PKB, Ca(2+) -dependent eNOS activation, soluble guanylate cyclase and modulation of vascular smooth muscle K(+) . Supporting data from BAEC indicated that nitrite production, intracellular Ca(2+) and PKB phosphorylation were increased after exposure to obestatin(1-23). Relaxations to obestatin(1-23) were unaltered by inhibitors of candidate endothelium-derived hyperpolarizing factors (EDHFs) and combined SK(Ca) /IK(Ca) blockade, suggesting that EDHF-mediated pathways were not involved. CONCLUSIONS AND IMPLICATIONS: Obestatin produces significant vascular relaxation via specific activation of endothelium-dependent NO signalling. These actions may be important in normal regulation of vascular function and are clearly relevant to diabetes, a condition characterized by endothelial dysfunction and cardiovascular complications.
BACKGROUND AND PURPOSE:Obestatin is a recently discovered gastrointestinal peptide with established metabolic actions, which is linked to diabetes and may exert cardiovascular benefits. Here we aimed to investigate the specific effects of obestatin on vascular relaxation. EXPERIMENTAL APPROACH: Cumulative relaxation responses to obestatin peptides were assessed in rat isolated aorta and mesenteric artery (n≥ 8) in the presence and absence of selective inhibitors. Complementary studies were performed in cultured bovine aortic endothelial cells (BAEC). KEY RESULTS:Obestatin peptides elicited concentration-dependent relaxation in both aorta and mesenteric artery. Responses to full-length obestatin(1-23) were greater than those to obestatin(1-10) and obestatin(11-23). Obestatin(1-23)-induced relaxation was attenuated by endothelial denudation, l-NAME (NOS inhibitor), high extracellular K(+) , GDP-β-S (G-protein inhibitor), MDL-12,330A (adenylate cyclase inhibitor), wortmannin (PI3K inhibitor), KN-93 (CaMKII inhibitor), ODQ (guanylate cyclase inhibitor) and iberiotoxin (BK(Ca) blocker), suggesting that it is mediated by an endothelium-dependent NO signalling cascade involving an adenylate cyclase-linked GPCR, PI3K/PKB, Ca(2+) -dependent eNOS activation, soluble guanylate cyclase and modulation of vascular smooth muscle K(+) . Supporting data from BAEC indicated that nitrite production, intracellular Ca(2+) and PKB phosphorylation were increased after exposure to obestatin(1-23). Relaxations to obestatin(1-23) were unaltered by inhibitors of candidate endothelium-derived hyperpolarizing factors (EDHFs) and combined SK(Ca) /IK(Ca) blockade, suggesting that EDHF-mediated pathways were not involved. CONCLUSIONS AND IMPLICATIONS: Obestatin produces significant vascular relaxation via specific activation of endothelium-dependent NO signalling. These actions may be important in normal regulation of vascular function and are clearly relevant to diabetes, a condition characterized by endothelial dysfunction and cardiovascular complications.
Authors: Mario Scrima; Pietro Campiglia; Cinzia Esposito; Isabel Gomez-Monterrey; Ettore Novellino; Anna Maria D'Ursi Journal: Biochem Biophys Res Commun Date: 2007-09-19 Impact factor: 3.575
Authors: Willis K Samson; Meghan M White; Christopher Price; Alastair V Ferguson Journal: Am J Physiol Regul Integr Comp Physiol Date: 2006-08-24 Impact factor: 3.619
Authors: A K Bassil; Y Häglund; J Brown; T Rudholm; P M Hellström; E Näslund; K Lee; G J Sanger Journal: Br J Pharmacol Date: 2006-11-27 Impact factor: 8.739
Authors: N Chartrel; R Alvear-Perez; J Leprince; X Iturrioz; A Reaux-Le Goazigo; V Audinot; P Chomarat; F Coge; O Nosjean; M Rodriguez; J P Galizzi; J A Boutin; H Vaudry; C Llorens-Cortes Journal: Science Date: 2007-02-09 Impact factor: 47.728
Authors: Marietta Anderwald-Stadler; Michael Krebs; Miriam Promintzer; Martina Mandl; Martin G Bischof; Peter Nowotny; Thomas Kästenbauer; Anton Luger; Rudolf Prager; Christian Anderwald Journal: Am J Physiol Endocrinol Metab Date: 2007-09-04 Impact factor: 4.310
Authors: Mohamed I Saad; Taha M Abdelkhalek; Moustafa M Saleh; Maher A Kamel; Mina Youssef; Shady H Tawfik; Helena Dominguez Journal: Endocrine Date: 2015-08-14 Impact factor: 3.633
Authors: E E Khirazova; M V Maslova; E S Motorykina; D A Frid; A V Graf; A S Maklakova; N A Sokolova; A A Kamenskii Journal: Dokl Biol Sci Date: 2014-01-03
Authors: Jacqueline M Ku; Zane B Andrews; Tom Barsby; Alex Reichenbach; Moyra B Lemus; Grant R Drummond; Mark W Sleeman; Sarah J Spencer; Christopher G Sobey; Alyson A Miller Journal: Endocrinology Date: 2015-01 Impact factor: 4.736
Authors: Brian D Green; Stewart F Graham; Elaine Cowan; Praveen Kumar; Kerry J Burch; David J Grieve Journal: Metabolomics Date: 2016-07-05 Impact factor: 4.290
Authors: Kvido Smitka; Hana Papezova; Karel Vondra; Martin Hill; Vojtech Hainer; Jara Nedvidkova Journal: Int J Endocrinol Date: 2013-09-09 Impact factor: 3.257
Authors: Junghwa Lim; Paul R Sabandal; Ana Fernandez; John Martin Sabandal; Hyun-Gwan Lee; Peter Evans; Kyung-An Han Journal: PLoS One Date: 2014-08-06 Impact factor: 3.240